跳至主要内容
临床试验/CTRI/2020/04/024855
CTRI/2020/04/024855招募中不适用

COMPARISON OF STANDARD 12 CORES SYSTEMATIC TRUS GUIDED BIOPSY AND MRI-FUSION BIOPSY IN THE DETECTION OF PROSTATE CANCER ¬– A PROSPECTIVE RANDOMIZED STUDY

HRD SCHEME OF DHR for Young scientist1 个研究点 分布在 1 个国家目标入组 180 人开始时间: 2018年3月12日最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
180
试验地点
1
主要终点
To evaluate the additional contribution by MRI-TRUS fusion targeted biopsy versus the standard 12 cores systematic TRUS guided biopsy in prostate cancer detection

研究概览

简要总结

Transrectal ultrasound-guided prostate biopsy (TRUS-Bx) has been thecornerstone of prostate cancer (PCa) diagnosis. As an extension of mpMRI, anovel and potentially transformative technique, MRI/TRUS fusion-guided biopsy,has recently emerged as an option for a more precise prostate biopsy. Considering the technical complexity due toimplementation of robots, complex software, specific material and the longerintervention time as well as the expensive cost, MRI/TRUS fusion biopsy cannotbe recommended for a routine application in all biopsy-naïve men with elevatedPSA.We intend to study theadditional role of mpMRI followed by MRI/TRUS fusion biopsy for PCa detectionas compared to the systematic 12 core TRUS guided biopsy in biopsy-naïve menwith elevated PSA and/or clinical suspicion of cancer by designing aprospective randomized study. The null hypothesize for this study is that thereis no difference in terms of PCa detection between systematic 12 core TRUSguided biopsy and mpMRI followed by MRI-TRUS fusion in biopsy-naïve men withelevated PSA level of 4-11 ng/ml and/or clinical suspicion of cancer.

研究设计

研究类型
Interventional
分配方式
Stratified block randomization
盲法
Open Label

入排标准

年龄范围
40.00 Year(s) 至 70.00 Year(s)(—)
性别
Male

入选标准

  • 1.Patients with elevated S.PSA level of 4-11 ng/ml 2.Suspected stage ≤ T2 on digital rectal examination 3.Signed informed consent.

排除标准

  • 1.Patients in whom MRI is contraindicated or not feasible 2.Previous history of prostate biopsy, prostate surgery or treatment of prostate cancer 3.Patients with active urinary tract infection 4.Patients with diffuse hard nodular prostate 5.Patients refusing participation in the study.

结局指标

主要结局

To evaluate the additional contribution by MRI-TRUS fusion targeted biopsy versus the standard 12 cores systematic TRUS guided biopsy in prostate cancer detection

时间窗: 18 MONTHS

次要结局

  • 1.Patients in whom MRI is contraindicated or not feasible(2.Previous history of prostate biopsy, prostate surgery or treatment of prostate cancer)

研究者

发起方
HRD SCHEME OF DHR for Young scientist
申办方类型
Government funding agency

研究点 (1)

Loading locations...

相似试验